Autoinflammatory & rare systemic diseases
Tocilizumab discontinuation after remission achievement in patients with adult-onset Still’s disease
Authors' conclusion
The recurrence rate after tocilizumab discontinuation was 50% in 1 year. Patients who remained in remission with a longer interval of tocilizumab administration and lower prednisolone dose were likely to succeed in the withdrawal of tocilizumab.
Study context
- Population
- Consecutive patients with adult-onset Still's disease (AOSD) (Yamaguchi's criteria), April 2012 to July 2022, treated with IV tocilizumab12 discontinued in remission
- Participants
- 48 patients
- Exposure
- Non-recurrence vs recurrence after tocilizumab discontinuation in remission
- Recurrencen = 6
- Non-recurrencen = 6reference
- Outcome
- Recurrence after tocilizumab discontinuation during remission
- Follow-up
- 1 year
Methodological detailsconsecutive patients
- Consecutive patients
Main finding
As reported in the abstract
Recurrence after tocilizumab discontinuation
Recurrence within 1 year, at a mean of 5.5 months
6
50.0%
Remained in remission
6
50.0%
Observational data: associations, not effects.
Further findings
Interval of tocilizumab administration at discontinuation · tended to be shorter in recurrence
P = 0.08
- Disease activity at tocilizumab discontinuation · no difference
- systemic feature score, P = 0.24
- Disease activity at tocilizumab discontinuation · no difference
- ferritin, P = 0.46
- Duration of tocilizumab use · not different
- P = 0.32
- Recurrence by prednisolone dose <7 mg/day at last tocilizumab treatment · Prednisolone <7 mg/day vs Prednisolone ≥7 mg/day · fewer recurrences with <7 mg/day
- P = 0.001
Remission after 6 months of tocilizumab
- Achieved remission
- 38 (79.2%)
Tocilizumab resumption after recurrence
- Resumed in half of the patients, resulting in successful disease control
Original publication
Tocilizumab discontinuation after remission achievement in patients with adult-onset Still’s disease. Rheumatology (Oxford). Published 20 March 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →